Abstract: Provided herein are drug implants comprising enzalutamide for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and enzalutamide disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may be used for the treatment of a proliferative disease of the prostate.

Abstract: Various embodiments provide for temperature-based read error handling on the memory system. In particular, some embodiments enable a memory system to handle an uncorrectable error for a read operation with respect to a memory device (of the memory system) based on a cross temperature associated with the read operation.

Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally, provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: Aspects of the present disclosure configure a system component, such as memory sub-system controller, to transition a state of a memory sub-system into different panic handling modes. The controller detects failure of a memory sub-system and determines that self-recovery from the failure of the memory sub-system is unavailable. The controller, in response to determining that self-recovery from the failure of the memory sub-system is unavailable, incrementally transitions a state of the memory sub-system to different panic handling modes and returns the memory sub-system to a deployed mode from one of the different panic handling modes in response to successfully recovering the memory sub-system.

Abstract: Aspects of the present disclosure configure a system component, such as a memory sub-system controller, to debug a memory sub-system. The controller receives, from a host over a first bus, authentication information associated with unlocking the debugging component and, in response to successfully authenticating the host based on the authentication information, unlocks a debugging component. The debugging component receives one or more debug commands from the host via a second bus and transmits, to the host via the second bus, debugging information in response to receiving the one or more debug commands.

Abstract: A memory device may comprise a memory controller configured for controlling access to an array of memory cells. The memory controller may be configured to perform one or more memory device functions that enable the host to perform system operations. The memory controller may include at least one safety mechanism and at least one safety mechanism monitor. The safety mechanism(s) may determine memory device fault condition(s) that has a potential to adversely affect performance of at least one of the one or more memory device functions. The safety mechanism monitor(s) may determine at least one safety mechanism fault condition that has a potential to adversely affect an ability of the safety mechanism(s) to determine the memory device fault condition(s). The host may assess whether the safety mechanism(s) is reliable based on the safety mechanism fault condition(s).

Abstract: A physical link comprising a set of lanes is configured according to a first lane configuration. In the first lane configuration, a first portion of the set of lanes is disabled and a second portion of the set of lanes serves traffic at a first link speed. A processing device, operatively coupled to the physical link, detects a change to bandwidth utilization of the physical link. In response to detecting the change to bandwidth utilization of the physical link, the processing device configures the set of lanes according to a second lane configuration. In configuring the set of lanes, the processing device configures the first portion of the set of lanes to serve traffic at a second link speed and disables the second portion of the set of lanes.

Abstract: Various embodiments provide for temperature-based read error handling on the memory system. In particular, some embodiments enable a memory system to handle an uncorrectable error for a read operation with respect to a memory device (of the memory system) based on a cross temperature associated with the read operation.

Abstract: A method for controlling aggregation for HRAM comprises a processing device, using a buffer manager, to receive instructions that include smaller-sized block write instructions from a host system. The processing device, using an aggregation engine, aggregates the smaller-sized block write instructions from the buffer manager into a plurality of larger-sized write instructions. The processing device issues a burst write instruction comprising the larger-sized write instructions to the memory component via the interface. The memory component can be HRAM and the interface can be a modified DDR-L5 interface for HRAM. Other embodiments are described herein.

Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally, provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: A method for controlling aggregation for HRAM comprises a processing device, using a buffer manager, to receive instructions that include smaller-sized block write instructions from a host system. The processing device, using an aggregation engine, aggregates the smaller-sized block write instructions from the buffer manager into a plurality of larger-sized write instructions. The processing device issues a burst write instruction comprising the larger-sized write instructions to the memory component via the interface. The memory component can be HRAM and the interface can be a modified DDR-L5 interface for HRAM. Other embodiments are described herein.

Abstract: Provided herein are drug implants comprising apalutamide for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and apalutamide disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may be used for the treatment of a proliferative disease of the prostate.

Abstract: Provided herein are drug implants comprising enzalutamide for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and enzalutamide disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may be used for the treatment of a proliferative disease of the prostate.

Abstract: Provided herein are drug implants comprising enzalutamide for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and enzalutamide disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may be used for the treatment of a proliferative disease of the prostate.

Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally, provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: Provided herein are drug implants comprising enzalutamide for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and enzalutamide disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may be used for the treatment of a proliferative disease of the prostate.

Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.